Showing 11 Abstracts.
03 : 38 PM
Bleeding with the FXI Inhibitor Abelacimab compared with Rivaroxaban in Patients on Antiplatelet therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial
Al Said Samer, Goodman Shaun, Joung Boyoung, Kiss Robert, Spinar Jindrich, Wojakowski Wojciech, Weitz Jeffrey, Bloomfield Dan, Sabatine Marc, Ruff Christian, Patel Siddharth, Giugliano Robert, Morrow David, Goodrich Erica, Murphy Sabina, Hug Bruce, Parker Sanobar, Chen Shih-ann
Final Pr. ID: 4143980
Authors: Al Said Samer , Goodman Shaun , Joung Boyoung , Kiss Robert , Spinar Jindrich , Wojakowski Wojciech , Weitz Jeffrey , Bloomfield Dan , Sabatine Marc , Ruff Christian , Patel Siddharth , Giugliano Robert , Morrow David , Goodrich Erica , Murphy Sabina , Hug Bruce , Parker Sanobar , Chen Shih-ann
Keywords: Anticoagulants, Antiplatelet drugs, Antithrombotic therapy, Atrial fibrillation, Rivaroxaban
07 : 00 PM
Characterization of Acute Ischemic Stroke (AIS) patients excluded from thrombolysis due to recent NOAC use.
Mok Kent, Palmisano Caitlin, Mcardle Patrick, Mehndiratta Prachi, Chaturvedi Seemant
Final Pr. ID: TP4
Authors: Mok Kent , Palmisano Caitlin , Mcardle Patrick , Mehndiratta Prachi , Chaturvedi Seemant
Keywords: Anticoagulants, Anticoagulation, Thrombolysis, Apixaban, Rivaroxaban
10 : 30 AM
Clinical Outcomes in Patients with Atrial Fibrillation and End-Stage Renal Disease Managed with Rivaroxaban versus Warfarin; A Propensity-Score Matched Analysis
Somerville Alexander, Anuforo Anderson, Rawlley Bharat, Ghosh Auyon
Final Pr. ID: Sa2076
Authors: Somerville Alexander , Anuforo Anderson , Rawlley Bharat , Ghosh Auyon
Keywords: Dialysis, Rivaroxaban, Warfarin, Atrial fibrillation, Mortality
05 : 00 PM
Comparative Effects of Apixaban and Rivaroxaban on Thrombin Generation Assessed by Viscoelastic Testing and Calibrated Thrombography
Rodriguez Alvarez Adriana, Ferlini Cieri Isabella, Patel Shiv, Boya Mounika, Dua Anahita
Final Pr. ID: Th0020
Authors: Rodriguez Alvarez Adriana , Ferlini Cieri Isabella , Patel Shiv , Boya Mounika , Dua Anahita
Keywords: Anticoagulants, Direct factor Xa inhibitor, Peripheral artery disease (PAD), Apixaban, Rivaroxaban
01 : 11 PM
Dual Pathway Inhibition prescription after percutaneous vascular intervention is low, and dependent on physician and treating facility practice patterns
Jarosinski Marissa, Lowenkamp Mikayla, Madigan Michael, Reitz Katherine, Chaer Rabih, Sridharan Natalie
Final Pr. ID: MP912
Authors: Jarosinski Marissa , Lowenkamp Mikayla , Madigan Michael , Reitz Katherine , Chaer Rabih , Sridharan Natalie
Keywords: Vascular surgery, Endovascular Therapy, Antithrombotic therapy, Big Data, Rivaroxaban
10 : 30 AM
Efficacy and Safety of Direct-Acting Oral Anticoagulants Compared to Vitamin K Antagonists for Atrial Fibrillation in Patients with Liver Cirrhosis: A Meta-Analysis
Ramos Miranda Maria Clara, Santos Charles Karel, Barbosa Gabriel, Nogueira Thallys, Da Silva Menezes Junior Antonio
Final Pr. ID: Sa2082
Authors: Ramos Miranda Maria Clara , Santos Charles Karel , Barbosa Gabriel , Nogueira Thallys , Da Silva Menezes Junior Antonio
Keywords: Atrial fibrillation, Direct factor Xa inhibitor, Warfarin, Apixaban, Rivaroxaban
03 : 30 PM
Exploring mediation through major bleeding between direct oral anticoagulants and cardiovascular (CV) events
Yuan Zhong, Schuemie Martijn, Weaver James, Barnathan Elliot
Final Pr. ID: MDP29
Authors: Yuan Zhong , Schuemie Martijn , Weaver James , Barnathan Elliot
Keywords: Atrial fibrillation, Anticoagulants, Cardiovascular, Outcomes, Rivaroxaban
09 : 30 AM
Gastrointestinal Bleeding Risk: Diltiazem versus Metoprolol in Patients on Rivaroxaban, Apixaban, or Dabigatran.
Seylani Allen, Haile Yohannes, Asiedu Samuel, Shahin Hania
Final Pr. ID: MDP1380
Authors: Seylani Allen , Haile Yohannes , Asiedu Samuel , Shahin Hania
Keywords: Arrhythmias, treatment of, Dabigatran, Apixaban, Rivaroxaban, Drugs
06 : 05 PM
Low-dose Rivaroxaban plus Antiplatelet Treatment in Patients With Symptomatic Intracranial Atherosclerotic Stenosis：A Prospective Observational Study
Zhang Ding, Zhao Zhaoyang, Qian Yiwei, Zhou Yifang, Pei Lulu, Cao Yuan, Song Bo
Final Pr. ID: TMP98
Authors: Zhang Ding , Zhao Zhaoyang , Qian Yiwei , Zhou Yifang , Pei Lulu , Cao Yuan , Song Bo
Keywords: Stroke, Intracranial atherosclerotic disease, Antithrombotic therapy, Rivaroxaban
10 : 30 AM
Pharmacosurveillance study of FDA Adverse Event Reporting System (FAERS) events of Apixaban and Rivaroxaban
Logvinsky Ilana, Maddineni Gautam, Wood Malissa, Delibasic Maja
Final Pr. ID: Sa2079
Authors: Logvinsky Ilana , Maddineni Gautam , Wood Malissa , Delibasic Maja
Keywords: Anticoagulants, Apixaban, Arrhythmias, treatment of, Rivaroxaban, Hemorrhage
12 : 32 PM
Walking Impairment Questionnaire score declines after lower extremity revascularization are linked to adverse cardiovascular events and rivaroxaban dose not affect walking ability
Kim Byung Gyu, Bauersachs Rupert M, Bonaca Marc, Patel Manesh, Debus Eike Sebastian, Nehler Mark, Anand Sonia, Hess Connie, Muehlhofer Eva, Haskell Lloyd, Berkowitz Scott
Final Pr. ID: MP1724
Authors: Kim Byung Gyu , Bauersachs Rupert M , Bonaca Marc , Patel Manesh , Debus Eike Sebastian , Nehler Mark , Anand Sonia , Hess Connie , Muehlhofer Eva , Haskell Lloyd , Berkowitz Scott
Keywords: Peripheral artery disease (PAD), Rivaroxaban, Quality assessment